Steeve DemoProfile
Oncology — Baylor Scott & White Health, United States
Steeve DemoProfile
LeadR Profile
Oncology
Subspecialties: Public Health - Therapeutics - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1995 - 2023
Number : 920
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection. sarcoma, neoplasms, safety, multivariate analysis, tissues, radiotherapy, adjuvant | Oncologist | 2023 | 5 |
| Radioligand therapies in cancer: mapping the educational landscape in Europe. education, teaching, nuclear medicine, universities, therapeutics, neoplasms | Eur J Nucl Med Mol Imaging | 2023 | 4 |
| Why will there never be a randomized trial for NTRK-rearranged tumors? neoplasms | Ann Oncol Top journal | 2023 | 8 |
| [Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]. neoplasms, morcellation, sarcoma, sarcoma, endometrial stromal, therapeutics | Bull Cancer | 2023 | 1 |
| Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. glioma, safety, molecular biology, neoplasms, thyroid carcinoma, anaplastic, therapeutics | Nat Med Top journal | 2023 | 160 |
Clinical Studies 103
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HDM201 and Pazopanib in Patients With P53 Wild type Advanced Metastatic Soft Tissue Sarcomas NCT05180695 — safety, pharmaceutical preparations, disease progression, sarcoma, genes, p53, response evaluation criteria in solid tumors, tissues | Phase 1/Phase 2 | Active not recruiting | 2022 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor NCT05059262 — cells, genes, dcc, safety, giant cell tumors, giant cell tumor of tendon sheath, neoplasms, double-blind method, tendons, giant cells, synovitis, pigmented villonodular, therapeutics, synovitis | Phase 3 | Active not recruiting | 2021 |
| Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist Ten) NCT05009927 — mesylates, gastrointestinal stromal tumors, neoplasms, tablets, maintenance, protein-tyrosine kinases, tyrosine, therapeutics, imatinib mesylate, mutation | Phase 2 | Recruiting | 2022 |
| Study of INBRX 109 in Conventional Chondrosarcoma NCT04950075 — cells, chondrosarcoma, apoptosis, cell death | Phase 2 | Active not recruiting | 2021 |
| Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) NCT04921553 — registries, genes, quality of life, data collection, proto-oncogene proteins c-sis, neoplasms, gene rearrangement, gene fusion, therapeutics, mutation | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map